CurieDx

Cover Block

PUBLIC

Name	CurieDx
Tagline	AI-driven smartphone app predicting infection risk from at-home or point-of-care test photos.
Headquarters	Baltimore, United States
Founded	2021
Stage	Seed
Business Model	B2B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.curiedx.com
• LinkedIn: https://www.linkedin.com/company/curiedx
• App Store: https://apps.apple.com/us/app/curiedx/id6496601748

Executive Summary

PUBLIC CurieDx is a digital diagnostics startup that uses smartphone cameras and AI to predict infection risk from photos of at-home tests, a proposition that merits investor attention for its potential to reduce unnecessary urgent care visits and streamline remote patient triage. The company was founded in 2021 as a spinout from Johns Hopkins University School of Medicine, where its co-founders, a pediatric emergency physician and a computer vision professor, developed the platform using clinically grounded datasets [Johns Hopkins Technology Ventures]. Its core product is an iOS app that analyzes images of throat swabs or urine test strips to screen for conditions like strep throat and UTIs, positioning itself as an "AI pocket doctor" that bridges home testing and telehealth [Johns Hopkins Technology Ventures, curiedx.com/strep-app]. Public funding information is limited, with support from the National Science Foundation and Johns Hopkins commercialization programs indicating an early, grant-backed stage of development. The business model targets a dual B2C and B2B2C approach, serving both consumers directly and clinicians via telehealth platforms [Johns Hopkins Technology Ventures, Blackburn Labs]. Over the next 12-18 months, the key watchpoints will be the transition from academic pilots to named commercial deployments, the expansion of its diagnostic panel beyond initial conditions, and the securing of its first priced equity round to fund scaling efforts.

Data Accuracy: GREEN -- Confirmed by multiple independent public sources including Johns Hopkins Technology Ventures, Crunchbase, and the company's website.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout

Company Overview

PUBLIC

CurieDx was founded in 2021 as a spinout from the Johns Hopkins University School of Medicine, where its initial development was supported by the university's technology commercialization arm [Johns Hopkins Technology Ventures]. The company is headquartered in Baltimore, Maryland, and presents itself as a woman and minority-owned business [LinkedIn]. Its founding was driven by a pediatric emergency physician's clinical need for faster, remote diagnostic tools, paired with a computer scientist's expertise in medical imaging AI.

The company's public milestones follow an academic-to-commercialization path typical of a university spinout. After its founding, it participated in accelerator programs including the MedTech Innovator Radar Forum and the JHU Hexcite program [Crunchbase]. The company has also secured non-dilutive grant support from the National Science Foundation [Crunchbase]. A key product milestone was the release of its first iOS application, "CurieDx," on the Apple App Store, which screens for strep throat using smartphone images [CurieDx, 2026] [Apple App Store].

Data Accuracy: YELLOW -- Core founding and location facts are confirmed by multiple sources, but some milestone details (like specific accelerator participation dates) rely on single database entries.

Product and Technology

MIXED

CurieDx's product is a smartphone application that uses computer vision to analyze user-captured images for signs of infection, positioning itself as a remote diagnostic aid rather than a definitive test. The publicly available iOS app, named CurieDx, focuses initially on screening for strep throat by comparing a photo of a user's throat against a proprietary AI model [curiedx.com/strep-app, 2026]. The company describes the output as a risk assessment, providing guidance to patients and clinicians on the likelihood of an infection to inform next steps, such as seeking in-person care or initiating telehealth consultation [Johns Hopkins Technology Ventures].

The technology stack is built around a clinically grounded dataset developed at Johns Hopkins, with model training led by co-founders specializing in pediatric emergency medicine and computer vision for medical imaging. The platform is designed to expand beyond strep throat; company materials indicate it can analyze images of other point-of-care tests, such as urine dipsticks for urinary tract infections [Johns Hopkins Technology Ventures]. For clinicians, the tool integrates into telehealth workflows to aid remote triage when physical tests are unavailable. The backend infrastructure and specific model architectures are not detailed publicly, though the engagement with software firm Blackburn Labs suggests development of a cloud-based, AI-powered diagnostic platform [Blackburn Labs].

Data Accuracy: YELLOW -- Product claims are consistent across the company website and university press, but technical implementation details and performance metrics are not publicly disclosed.

Market Research

PUBLIC The market for remote, AI-assisted diagnostics is coalescing around a clear demand: reducing the friction and cost of accessing basic healthcare for common conditions. This is not a speculative future market but a response to documented pressures within the U.S. healthcare system, including persistent primary care shortages and rising patient expectations for convenience [JHU Hub, 2024].

CurieDx's initial focus on strep throat and urinary tract infections (UTIs) targets a substantial portion of acute care visits. While the company does not disclose its own market sizing, analogous public reports illustrate the scale of the opportunity. The global point-of-care diagnostics market was valued at approximately $40 billion in 2023, with rapid test segments for infectious diseases representing a significant portion [Grand View Research, 2023]. More specifically, the market for at-home strep tests and telehealth services for acute conditions is a multi-billion dollar segment, driven by the volume of annual visits. For context, there are an estimated 11 million visits for sore throat in the U.S. each year, with a substantial portion potentially suitable for remote triage [CDC, 2022].

Demand is propelled by several converging tailwinds. The normalization of telehealth post-pandemic has created patient and provider comfort with remote consultations. Simultaneously, health systems face economic pressure to reduce low-acuity emergency department and urgent care visits, which are costly settings for conditions like strep throat. The proliferation of smartphone cameras and improved computational photography provides the necessary hardware infrastructure for image-based diagnostics at near-zero marginal cost to the user. These drivers suggest a receptive environment for tools that can accurately filter patients before they seek in-person care.

Key adjacent and substitute markets influence the competitive dynamics. CurieDx's solution sits at the intersection of several larger categories:

• Direct-to-consumer lab testing (e.g., Everlywell, LetsGetChecked), which offers mail-in kits but involves shipping delays.
• Telemedicine platforms (e.g., Teladoc, Amwell), which provide the clinician consultation but often lack integrated, immediate diagnostic tools.
• Traditional at-home rapid tests sold at pharmacies, which provide a physical result but no digital interpretation or connection to care guidance. The company's wedge appears to be integrating the immediacy of a physical test with the interpretive power of AI and a pathway to a telehealth prescription, attempting to capture value across this chain.

Regulatory and macro forces present both a gating mechanism and a potential moat. As a software intended to inform clinical decision-making for diagnosis, CurieDx's core AI likely requires FDA clearance as a Software as a Medical Device (SaMD). The path to and timing of such clearance is a critical, non-public variable that will dictate commercial scalability with enterprise healthcare clients. Macro forces, including payer reimbursement for remote diagnostic services and evolving state telemedicine laws, will ultimately determine the economic model's viability beyond a direct-to-consumer purchase.

Metric	Value
Global POC Diagnostics Market (2023)	40 $B
U.S. Sore Throat Visits (Annual)	11 million

The chart underscores the addressable volume, though CurieDx's specific serviceable market is a fraction of these totals, contingent on regulatory approval and adoption by telehealth providers.

Data Accuracy: YELLOW -- Market sizing figures are from analogous, third-party industry reports and public health data, not company-specific projections. Tailwind analysis is supported by cited trends in telehealth adoption and healthcare economics.

Competitive Landscape

MIXED CurieDx enters a diagnostic market where competition is defined not by a single direct rival, but by a fragmented landscape of incumbent workflows, digital challengers, and adjacent substitutes.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
CurieDx	AI-driven smartphone app for infection risk prediction from test photos. B2B2C model.	Seed stage. Undisclosed funding. Johns Hopkins spinout.	Clinically grounded AI from academic medical center; dual patient/clinician interface.	[Johns Hopkins Technology Ventures] [LinkedIn]
Healthy.io	Turns smartphone into FDA-cleared urinalysis device via dipstick analysis kit.	Later stage. $277M+ raised [PitchBook, 2025].	FDA 510(k) clearance for ACR (kidney disease) and UTI tests; commercial contracts with health systems and payers.	[Crunchbase, 2025]
Scanwell	Smartphone-based at-home test reader app (UTI, ovulation, etc.) linked to telehealth.	Acquired by Everlywell (2021).	Integrated telehealth prescription service; consumer brand recognition via acquisition.	[TechCrunch, 2021]

The competitive map breaks into three segments. Incumbent workflows are the default: in-person urgent care visits for rapid strep tests and standard urinalysis labs. These are not startups but established care pathways, and they compete on clinical certainty and insurance reimbursement, not convenience. Digital challengers include companies like Healthy.io and the now-acquired Scanwell, which have pursued FDA-cleared, hardware-linked smartphone readers for specific tests, often with a direct-to-consumer or DTC-plus-telehealth model. Adjacent substitutes include symptom-checker apps (e.g., Ada Health) and pure-play telehealth platforms that rely on patient self-reporting without image analysis.

CurieDx’s defensible edge today rests on two pillars. First, its academic-clinical dataset and development environment at Johns Hopkins provides a moat of clinically validated imagery that consumer app developers cannot easily replicate [Johns Hopkins Technology Ventures]. Second, its dual-interface strategy,serving both patients for screening and clinicians for triage,aims to embed the tool within existing telehealth workflows rather than replacing them. This edge is perishable, however. The dataset advantage erodes if a well-funded competitor licenses similar academic data or aggregates a larger, real-world image corpus through commercial deployments. The workflow integration is not yet proven at scale outside its academic home.

The company’s most significant exposure is to the regulatory and commercial scale achieved by competitors like Healthy.io. Healthy.io’s FDA clearances and payer contracts create a high barrier to entry for the same clinical indications [PitchBook, 2025]. CurieDx’s current public positioning around strep throat screening, while a clear initial wedge, does not yet show the same level of regulatory maturity or enterprise sales traction. Furthermore, its model depends on patient-captured images, which introduces variability that hardware-bound solutions (like a calibrated dipstick reader) are designed to control.

The most plausible 18-month scenario hinges on distribution. The winner will be whichever entity successfully converts its technological wedge into a reimbursed clinical pathway. If CurieDx can secure a pilot with a major telehealth provider or health system that leads to a billing code, its academic validation could translate into durable adoption. Conversely, if a competitor like Healthy.io expands its FDA clearances into strep throat or other point-of-care tests and leverages its existing commercial relationships, CurieDx could be relegated to a niche academic tool. The loser in this scenario is any player that remains a consumer-facing symptom checker without demonstrable clinical utility and reimbursement.

Data Accuracy: YELLOW -- Competitor profiles are confirmed by public funding databases and news reports; CurieDx's competitive positioning is inferred from product claims and market context.

Opportunity

PUBLIC

If CurieDx successfully proves its AI can reliably triage common infections at scale, it could become the default pre-visit screening layer for a significant portion of the $50 billion (estimated) U.S. urgent care and telehealth market, reducing millions of unnecessary clinical encounters annually.

The headline opportunity is for CurieDx to evolve from a point-solution app into a category-defining remote diagnostic platform, becoming the de facto standard for initial infection screening before a patient steps into a clinic or initiates a telehealth call. This outcome is reachable because the company’s foundational work addresses a clear, high-volume clinical bottleneck: the triage of common, visually diagnosable conditions like strep throat and UTIs. The platform’s design, described as an "AI pocket doctor" that lives on a patient’s smartphone, directly targets the inefficiency of in-person visits for preliminary assessment [Johns Hopkins Technology Ventures]. Its academic origin at Johns Hopkins School of Medicine provides a credible, clinically grounded starting point for the AI models, which is a critical differentiator in a field where regulatory and clinical trust are paramount.

Growth from early pilots to massive scale would likely follow one of several concrete paths. The scenarios below outline plausible, evidence-supported routes to becoming a significant platform.

Scenario	What happens	Catalyst	Why it's plausible
Embedded Telehealth Standard	Major telehealth providers (e.g., Teladoc, Amwell) integrate CurieDx’s screening API into their intake workflows to improve triage accuracy and reduce unnecessary antibiotic prescriptions.	A partnership with a single, large telehealth platform, announced as a pilot program.	The company’s stated use case is for clinicians and telehealth providers to guide care remotely when tests are limited [Johns Hopkins Technology Ventures]. Its B2B2C model is built for this channel.
Health System Land-and-Expand	A large integrated delivery network (e.g., Johns Hopkins Medicine) adopts the tool for its affiliated urgent care centers and patient portal, creating a proven deployment blueprint.	A published clinical validation study from the company’s academic founders, demonstrating non-inferiority to standard rapid tests.	The founding team’s deep roots within Johns Hopkins provide a natural, high-trust testing ground for initial enterprise sales and clinical workflow integration.
Consumer Direct-to-Diagnostic	The app gains traction as a trusted at-home screening tool, driving user-paid subscriptions or test-kit bundling deals with retailers, creating a standalone DTC brand.	Feature expansion beyond strep throat to include a suite of common conditions (e.g., pink eye, skin infections), validated by the FDA.	The app is already available on the Apple App Store for patient use, and the company markets directly to parents for at-home screening [CurieDx, 2026].

The compounding effect for CurieDx would be a classic data network effect. Each new image analyzed, particularly from diverse clinical settings and patient demographics, would refine the AI model’s accuracy. This creates a data moat: a more accurate model attracts more users (both patients and clinicians), which in turn generates more proprietary training data, further widening the performance gap against competitors who lack similar volume or clinical provenance. Early evidence of this flywheel is not yet public, but the company’s collaboration with a software development firm to build its "AI-powered diagnostic platform" suggests an infrastructure designed to handle scaling data ingestion and model iteration [Blackburn Labs].

Quantifying the size of the win requires looking at comparable outcomes. Healthy.io, a competitor that turns smartphones into clinical-grade urinalysis devices, reached a valuation reportedly over $500 million following its Series D round in 2021 [Crunchbase]. If CurieDx executes on the "Embedded Telehealth Standard" scenario and captures a material portion of the U.S. telehealth triage market, a similar valuation range is plausible within a 5-7 year horizon (scenario, not a forecast). The prize is not merely the app itself, but the potential to own the initial diagnostic interaction for a slate of high-incidence conditions, a position that could command platform-level economics.

Data Accuracy: YELLOW -- Opportunity size and scenarios are analyst projections based on cited market logic and company positioning; competitor valuation is a single public data point.

Sources

PUBLIC

1. [Johns Hopkins Technology Ventures] 10 Innovations in 10 Years: CurieDx | https://ventures.jhu.edu/news/10-innovations-in-10-years-curiedx/

2. [LinkedIn] CurieDx | LinkedIn | https://www.linkedin.com/company/curiedx

3. [Crunchbase] CurieDx - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/curiedx

4. [CurieDx, 2026] App to screen for strep throat: StrepAI | https://www.curiedx.com/strep-app

5. [Apple App Store] CurieDx on the Apple App Store | https://apps.apple.com/us/app/curiedx/id6496601748

6. [Blackburn Labs] CurieDx | Projects | Blackburn Labs | https://blackburnlabs.com/projects/curiedx/

7. [JHU Hub, 2024] JHU Hub article on CurieDx | https://hub.jhu.edu/2024/02/27/curiedx-app-strep-throat/

8. [Grand View Research, 2023] Point-of-Care Diagnostics Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/point-of-care-diagnostics-market

9. [CDC, 2022] CDC data on sore throat visits | https://www.cdc.gov/nchs/fastats/sore-throat.htm

10. [PitchBook, 2025] Healthy.io Company Profile | https://pitchbook.com/profiles/company/150783-10

11. [TechCrunch, 2021] Everlywell acquires Scanwell Health | https://techcrunch.com/2021/01/11/everlywell-acquires-scanwell-health/